← Back to Clinical Trials
Recruiting NCT06713603

NCT06713603 Technology Assisted Motivational Interviewing

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06713603
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Smoking
Study Type INTERVENTIONAL
Enrollment 440 participants
Start Date 2025-09-22
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
TAMI Coach

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 440 participants in total. It began in 2025-09-22 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Building on our successful pilot work to develop a Motivational Interviewing (MI)-capable chatbot and cessation coach, the investigators propose to address the problems of intrinsic motivation and social barriers to smoking cessation by evaluating a highly scalable and easily accessible digital-coaching intervention that 1) promotes readiness to change using a technology-assisted MI (TAMI) chatbot, 2) provides compelling and accessible multilingual education about smoking cessation tools, and 3) develops a tailored quit plan addressing social barriers to treatment initiation and sustainment.

Eligibility Criteria

Inclusion Criteria: * A current Primary Care Provider patient * Age 18 or older * Smoke at least 1 cigarette per day for the past 7 consecutive days (and at least 100 lifetime) * Have a digital device (phone, laptop, tablet) * Moderately proficient in English * Able to participate for 6-month trial Exclusion Criteria: * Current participation in a smoking cessation program * Current use of Nicotine Replacement Therapy or smoking cessation pharmacotherapy * Cognitive impairment that would preclude informed consent

Contact & Investigator

Central Contact

Jason Satterfield, PhD

✉ Jason.Satterfield@ucsf.edu

📞 415-353-2104

Principal Investigator

Jason Satterfield, PhD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06713603 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06713603 currently recruiting?

Yes, NCT06713603 is actively recruiting participants. Contact the research team at Jason.Satterfield@ucsf.edu for enrollment information.

Where is the NCT06713603 trial being conducted?

This trial is being conducted at San Francisco, United States, San Francisco, United States.

Who is sponsoring the NCT06713603 clinical trial?

NCT06713603 is sponsored by University of California, San Francisco. The principal investigator is Jason Satterfield, PhD at University of California, San Francisco. The trial plans to enroll 440 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology